Sign in

    James Bogin • Legend Capital

    James Bogin is an analyst at Legend Capital, with a focus on investment research across a range of sectors. He brings extensive experience to the role, though specific details about the exact companies he covers, his performance track record, or rankings on platforms like TipRanks are not publicly available. Prior to joining Legend Capital, Bogin's career history and professional credentials are not disclosed in publicly accessible profiles, and there is no verifiable record of FINRA registration or securities licenses. Without detailed performance metrics or a more robust public profile, further specifics about his achievements or recognition in the field cannot be confirmed.

    James Bogin's questions to FitLife Brands Inc (FTLF) leadership

    James Bogin's questions to FitLife Brands Inc (FTLF) leadership • Q1 2025

    Question

    James Bogin asked about the long-term prospects for the MusclePharm brand, noting its significant sales decline from historical peaks, and also inquired about the company's broader strategic goals, such as whether the plan is to build an empire or seek an acquisition.

    Answer

    Executive Dayton Judd acknowledged disappointment with MusclePharm's growth trajectory but stressed that the acquisition was structured to be a good deal even without growth. He explained that the company is now investing in growth but can pivot if the strategy is unsuccessful. Regarding long-term strategy, Judd stated that FitLife is in the "fifth or sixth inning" and sees a tremendous opportunity for M&A and consolidation in the fragmented supplement industry, which is the current focus over a near-term sale.

    Ask Fintool Equity Research AI

    James Bogin's questions to FitLife Brands Inc (FTLF) leadership • Q4 2024

    Question

    Asked about MusclePharm's historical peak sales and future potential, the reason for the stock's negative reaction to the earnings report, and the potential for improving MusclePharm's gross margins.

    Answer

    MusclePharm's historical peak sales of over $175M are considered unreliable and unachievable; a fraction of that would be a success. The executive cannot explain daily stock price movements but is focused on long-term value and potential M&A opportunities from market dislocation. MusclePharm's gross margins are being intentionally suppressed by promotional spending to invest in growth and could be increased by cutting promotions, but that is not the current strategy.

    Ask Fintool Equity Research AI